上海会森胜网络科技有限公司
20人以下
公司优势
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
克拉玛依经营灯具店15年。
SPH KDL Health (Chongqing) Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is a holding subsidiary of SPH Group, which is managed by the State-owned Assets Supervision and Administration Commission of Shanghai Municipality. The parent company, Shanghai Pharma Group, is a leading enterprise in the pharmaceutical industry in China. Its business covers the entire industrial chain of pharmaceutical research and development, manufacturing, distribution, retail, and investment. In 2020, it entered the list of the world's top 500 companies, ranking 473, and ranked 57 among the top 500 listed enterprises in China (A+H). It is also ranked 48th globally in the pharmaceutical industry, 24th globally in pharmaceutical brands, and among the top three in the Chinese pharmaceutical industry. In 2019, the company achieved an operating revenue of 186.6 billion yuan, ranking 43rd among the top 500 Chinese manufacturing enterprises, 93rd in the "China Brand Development Index" 100 list by the People's Daily, and 25th in global pharmaceutical brand value.
The Chongqing company was established in 1993, formerly known as Chongqing Pharmaceutical Development Company under the Chongqing Pharmaceutical Administration, with a registered capital of 50 million yuan, located at No. 137 Keyuan Second Road, Jiulongpo District, with 115 employees. The company is dedicated to diversified supply chain services such as drugs and medical devices and is a mainstream pharmaceutical circulation enterprise in Chongqing. It ranks second in the transaction and distribution amount of medical institutions in the Chongqing Drug Exchange. It is authorized by over a thousand manufacturers and can deliver more than 15,000 product specifications. The company is also the only national pharmaceutical circulation enterprise in Jiulongpo District and has been selected as one of the designated distribution members of the Jiulongpo District consortium for two consecutive terms, undertaking the security supply of nearly a thousand product specifications of medicines in 22 medical institutions in Jiulongpo District.
The company has received titles such as "Vice Chairman Unit of Chongqing Pharmaceutical Industry Association," "Vice Chairman Unit of Chongqing Medical Insurance Research Association," "Vice Chairman Unit of Chongqing Jiulongpo Pharmaceutical Chamber of Commerce," and "Jiulongpo District Model and Demonstration Wholesale Enterprise." It has been inspected and guided by the State Food and Drug Administration, district government, and district People's Congress multiple times.
In 2020, the company achieved an operating revenue of 1.56 billion yuan (including tax) and paid taxes of 16.69 million yuan. During the 2020 pandemic, the company was designated as a "Chongqing Epidemic Prevention Material Reserve Unit" and contributed positively to the city's fight against the epidemic, earning the title of "Special Contribution Enterprise for Epidemic Resistance."
The company will continue to rely on the strong headquarters resources of SPH Group, adhering to a customer-centric service philosophy, compliance, integrity, and transparent management requirements, to better fulfill its responsibilities in serving medical reform and society, safeguarding people's livelihood, and serving the vast number of patients in the area, making new contributions to the medical and health reform of Jiulongpo District.
永康市康集工贸有限公司，公司规模少于50人，公司类型民营公司，所属行业贸易/进出口。
ABclonal集结了一支由来自哈佛大学、麻省理工学院、复旦大学、上海交通大学、中国科学院生物化学与细胞研究所及武汉大学的全球顶级分子生物学和免疫学博士组成的科学团队，依托美国波士顿抗体与蛋白研发中心、中国光谷生物城（武汉）抗体生产基地以及上海张江分子酶研发中心，专注于抗体与蛋白技术的研究。公司业务范围广泛，涵盖科研抗体、分子酶产品、NGS建库试剂盒、活性重组蛋白、诊断抗原抗体原料、ELISA试剂盒以及合同研究组织（CRO）服务。
CRO服务包括抗体与蛋白技术、基因与多肽合成、免疫学检测及ChIP-seq技术服务等。ABclonal致力于为全球科研机构、药物研发单位及诊断工业客户提供优质产品和专业服务。
公司专注于抗体与蛋白平台的建设和优化，持续引进先进技术和方法，力求达到世界领先水平。抗体平台包括兔多克隆抗体、小鼠单克隆抗体以及最新的兔单克隆抗体平台。其中，兔多克隆抗体平台已完成人类基因组多克隆抗体的研发工作；鼠单克隆抗体平台支持每年500多个CRO服务订单及诊断抗体试剂的开发；兔单克隆抗体平台则专注于全球热门科研与诊断抗体试剂的开发。
蛋白平台聚焦于全球顶尖分子酶试剂技术的开发以及原核与真核四大蛋白表达技术的优化。公司规划的分子酶与活性重组蛋白GMP生产线即将投入使用。
ABclonal的研发平台与市场渠道相辅相成，共同推动公司的快速发展。公司致力于打造全球领先的抗体与蛋白试剂品牌。
企业优势：
- 丰富的科研资源
- 专业的科学家团队
- 完善的全球分销网络
- 高品质的分子与免疫学产品
企业历史：
- 2006年：ABclonal在美国波士顿剑桥成立，专注于抗体制备和多肽合成等CRO服务。
- 2008年：启动人类基因组抗体库研发计划，开始抗体研发项目。
- 2011年：在中国光谷生物城（武汉）建立抗体生产基地和实验动物中心，继续推进人类基因组抗体库研发。
- 2012年至2015年：抗体研发项目数量达到每年4000项，成功上线超过10000种抗体产品，全球渠道覆盖多个国家，建立美国波士顿和中国武汉两大库存点。
- 2016年：完成数千万美元融资，在美国波士顿设立抗体与蛋白研发中心，提供全球近50个国家的CRO服务。
- 2017年：在上海张江成立分子酶研发中心，进入分子酶试剂和NGS建库试剂盒领域。
- 2018年至2019年上半年：完成近亿元B轮融资，兔单抗技术在武汉落地，欧洲分公司与办事处成立，日本分公司成立。
- 2020年：完成C轮六亿融资，研发新冠蛋白类产品及蛋白酶K产品，提前完成年度业务目标。
核心技术：
- 抗体平台：规模化多克隆抗体平台、鼠单克隆抗体平台、兔单克隆抗体平台、ELISA Kit研发平台、抗体测序平台。
- 蛋白平台：分子酶平台、规模化原核系统蛋白平台、完善的真实核系统蛋白平台、GMP级药物蛋白开发平台。
武汉佩尔中心儿童之家成立于2017年9月，秉承蒙特梭利博士的教育理念，全校主班教师均获得国际蒙特梭利协会（AMI）任职资格，致力于打造优质蒙特梭利教育机构，为孩子营造独立自主、充满关爱的真实环境。
佩尔中心儿童之家位于汤逊湖畔，占地5800平米，其中户外面积2800平米，室内面积2600平米，开设2个0-3岁IC班、3个3-6岁CASA班及1个6-12岁宇宙教育班，确保每位孩子拥有5平米的学习空间。教具选用AMI推荐的荷兰NIENHUIS品牌，园区三面环湖，绿树环绕，在优美的自然环境中配备动/植物养殖区、室内外运动场，让孩子们在理想环境中生活、学习和成长。